Hypertension arising during pregnancy remains one of the two most frequently-cited causes of maternal death in the UK. In some cases, pregnancy is unmasking underlying hypertension, which manifests itself in later life. Pregnant women who develop de novo proteinuric hypertension (pre-eclampsia, PE) can share many risk factors with patients with the metabolic syndrome, such as obesity, dyslipidaemia and insulin resistance. However, more than half the women who develop PE remain normotensive thereafter. There is a genetic component(s) to the disease, but it is most improbable that there is a 'PE gene'. Rather, there are factors such as geneticallydetermined thrombophilias which are predisposers but not prerequisites. Impaired placentation is a feature, with inadequate invasion of the spiral arteries by syncytiotrophoblast and poor remodelling. However, similiar features are found in association with non-hypertensive
Introduction
It is a lamentable fact that, until relatively recently, there was little basic research in obstetrics. Observation certainly, and consideration of management regimes, but investigations into the physiology and pathophysiology of pregnancy were the province of a few dedicated individuals. Convulsions in pregnancy have been noted since at least the time of Galen (4th century BC). As maternal death rates fell in the 20th century AD, at first slowly, then much more rapidly after the introduction of antibiotics, and with improving antenatal and peri-partum care, so the relative importance of the 'toxaemias' of pregnancy as causes of maternal death increased. They have, however, always been one of the 'Big Four', the others being infection, thrombosis and haemorrhage. A quick scan of Medline reveals that in 1969, a mere 22 articles with the keyword 'pre-eclampsia' or 'preeclampsia' were published. By 1979 this had risen to 115 and to 285 in 1989. A scan in late 1999 identified 468 such publications, and whereas 30 years ago, more than half of the papers were case reports or related to management, those today are far more likely to be concerned with basic science, utilising extremely sophisticated methodology and collaboration with colleagues across numerous disciplines.
However, pregnancy remains a higher-risk state than non-pregnancy. In the most recent 'Report on Confidential Enquiries into Maternal Deaths in the United Kingdom', 1 which is believed to have neartotal ascertainment, pre-eclampsia/eclampsia remain one of the two most frequently-cited causes of maternal death, as they have for the last 30 years. In the United Kingdom, as in North America, the absolute numbers of maternal deaths are relatively small 1 (USA 9.2/100000 and UK 12.2/100 000 maternities;
1,2 but in less developed countries, such as Central and parts of South America and sub-Saharan Africa, rates, where available, can be 20-30 times higher (eg, Mungra et al, 1999 ; 3 Etard et al, 1999). 4 As usual, the Greeks had a word for it. The word? Eclampsia, the thunderbolt, which strikes from the blue, and can kill where it strikes. A prospective study which attempted to involve every consultant obstetrician in the United Kingdom reported an incidence of eclampsia of 4.9/10 000 maternities. 5 Eleven percent had no recorded hypertension or proteinuria at the antenatal clinic visit immediately preceding the onset of fitting, and a further 10% had proteinuria but no hypertension. Even in those who had been admitted to hospital, the highest recorded diastolic pressure before the onset of convulsions was 100 mm Hg or less in a third (34%). Diastolic pressures of 120 mm Hg or more before fitting were only recorded in 19% of patients. Thus it is unsafe to consider eclampsia as being the end-point of severe pre-eclampsia, although it can be associated. Interestingly, a careful follow-up of 65 patients 6-42 months after eclampsia found that none of the women had neurological deficits after 6 months or repeated convulsions, 6 emphasising that it is a pregnancy-related condition. Of the 38 who subsequently had one or more pregnancies, none had a recurrence of fitting.
The relatively low incidence of eclampsia, and its diversity of presentation, make systematic study of its pathogenesis very difficult indeed. This being so, the remainder of this paper will not consider it further, and will focus on the several hypertensive conditions found in pregnancy.
Definitions
The question of the definition of the various forms of hypertension found in pregnancy has exercised numerous groups, and serious attempts are being made in 1999/2000 to arrive at an agreed definition for research purposes, which may be used worldwide. For purposes of this paper, gestational hypertension (GH; also referred to as 'pregnancy-induced hypertension', PIH) is defined as the occurrence of an increase of at least 30/15 mm Hg in the blood pressure from pre-or early-pregnancy levels or an absolute value of at least 140/90 mm Hg or more on at least two occasions not less than 4 -6 h apart in a woman known to have been normotensive before 20 weeks of gestation and in whom the blood pressure has returned to normal by, at the latest, the twelfth week post-partum. 7 Korotkov sound V has now been accepted as preferable for recording the diastolic pressure in pregnancy (eg, Shennan et al 8 ) . When this is accompanied by de novo significant proteinuria (Ͼ300 mg/l or 500 mg/day in a 24-h urine sample, or a minimum of two 'pluses' of protein on dipstick test), which also resolves after delivery, the condition is known as pre-eclampsia (PE). Pre-eclampsia may also be accompanied by any/all of haemolysis, elevated liver enzymes and a platelet count below 100 × 10 9 cells/l (thrombocytopaenia). When all are present, the condition is known as HELLP. Any of these conditions may be superimposed upon pre-existing essential hypertension.
There is discussion as to whether GH and PE are indeed part of the same spectrum of disease. This is enhanced by the observation that GH at term is usually associated with normally-grown, or even slightly large, babies, particularly when centiles defined for the specific population are used (reviewed in MacGillivray, 1983 9 ). Conversely, nulliparous women with PE have a four-fold greater likelihood of delivering a baby small for its gestational age than do normotensive nullips 10 ). Saudan et al (1998) 11 reported that 15-25% of women diagnosed initially with GH went on to develop PE, the likelihood being greater the earlier in pregnancy the hypertension developed. It may simply be that later-onset GH does not have time to develop into PE. Conversely the other 85% of women may have different, benign disease. This latter possibility is supported by epidemiological observations that indicate a greater risk of recurrence and essential hypertension in later life for women with GH than those with PE. Additionally, many of the characteristic markers of physiological abnormalities of PE such as increased cellular fibronectin concentrations are not present in GH. 12 If one imagines that GH may be a physiological mechanism to compensate for impaired utero-placental perfusion (see 'Conclusion'), and PE a pathological breakdown of such a system, then the different outcomes become more comprehensible. It certainly seems improbable that a condition should occur with such frequency (GH ෂ10% in first pregnancy) at such a physiologically important time of life if it were wholly malign.
Problems
The fact that the defining symptoms of hypertension and significant proteinuria arising de novo only become apparent late in the disease process, and are secondary, not primary, phenomena is a further obstacle to research. The seeds of PE are sown very early indeed in pregnancy. To compound the problem still further, the actual measurement of the blood pressure is notoriously unreliable, and inclusion criteria have differed from study to study. Worse still, the determination of the level of the blood pressure even in normotension is itself multifactorial.
Heterogeneity of study groups
Apparent PE occurring in a second or subsequent pregnancy is associated with a considerably higher incidence of hypertension in later life than if the condition occurs only in the first pregnancy. 13 Parous women who develop PE or eclampsia are twice as likely to die from ischaemic heart disease in later life than are women who develop PE or eclampsia in their first pregnancy.
14 Furthermore, renal biopsy performed in primiparous and multiparous women diagnosed as having PE showed that while 84% of primiparae did have diagnostic glomerular endotheliosis, only 28% of multiparae did so. 15 Thus pathophysiological studies should logically concentrate on women who develop PE in their first pregnancy.
Another problem is that the diagnosis undoubtedly encompasses more than one condition. For example, in a prospective study of 212 primigravidae, it was noted that 50 had had an isolated 'spike' of systolic blood pressure of 140 mm Hg or more during their first antenatal visit to their general practitioner, but were normotensive by the time of their first hospital antenatal clinic appointment. However, these women were twice as likely to be diagnosed as having either non-proteinuric or proteinuric hypertension (PE) in pregnancy as those who did not show such a spike. Furthermore, other differences were noted between the groups (Table  1 ).
An increased urinary calcium excretion is common in essential hypertension (eg, Robinson, 1984 17 ), while renal vasoconstriction and reduction 16 of renal blood flow are early companions of cardiac insufficiency, and will stimulate the renin-angiotensin system. The angiotensin-converting enzyme inhibitors and, more recently, the angiotensin AT1 receptor blockers, are widely used in the treatment of essential hypertension, and are highly effective (see Nicholls et al, 1998 18 ). It therefore seems likely that this form of 'white coat hypertension', under the stressful circumstances of a first antenatal visit, may be identifying a cohort of women who will be diagnosed as having GH or PE when in fact they have underlying chronic hypertension.
The pathogenesis of GH and PE is almost certainly multifactorial. This being so, simplistic efforts to determine a single 'cause' are likely to be doomed to discouraging failure. Even when PE recurs in the same patient, it may do so in a rather different guise. An example of this is given by a patient in Nottingham. Normotensive at the start of her first pregnancy, she had by 24 weeks gestation suffered a rise of 35 mm Hg in both systolic and diastolic blood pressure. By 3 days later, her blood pressure had reached 200/120 mm Hg in spite of ␣-methyl dopa therapy and her platelet count had dropped from 187 to 70 × 10 9 cells/l. Over the same period, her serum alanine transaminase (ALT) had risen from 22 to 140 U/l but the alkaline phosphatase, serum urate and albumin concentrations remained within the normal range. She was delivered by emergency Caesarean section of a grossly growth-retarded infant who died shortly after delivery. Her blood pressure was 120/70 mm Hg by 2 weeks post-partum. Thirty months later she conceived by another partner, and was normotensive at 15 weeks gestation. Again, she became severely hypertensive at 23 weeks gestation, with worsening hypertension in spite of therapy. Attempts were made to prolong the pregnancy for the sake of fetal maturation, but at 28 weeks, her blood pressure control was lost (180/115 mm Hg) and delivery was effected by Caesarean section. In this pregnancy, her platelet count over the last few days ranged between 224 and 317 × 10 9 cells/l and ALT between 16-25 U/l, with normal serum alkaline phosphatase and urate concentrations. However, this time her serum albumin concentration fell steadily as the disease worsened, to a nadir of 24 g/l in conjunction with urinary protein output of 5.72 g/l. Thus although she clearly developed pre-eclampsia in both pregnancies, the associated system disorders were different.
Journal of Human Hypertension

Specific study areas
Genetics
Given all this, it is hardly surprising that research into the causes of PE has not proceeded faster. One area currently attracting increasing attention is that of the genetics of the condition. A pioneer of research into PE, Professor Leon Chesley, showed in his three-generation follow-up study that there is at least a genetic predisposition to the condition (see: Lindheimer et al, 1999 19 ). All the requirements for scrupulous, standardised phenotyping come into play here. This is no single-gene disease such as cystic fibrosis; we will not identify a 'pre-eclampsia gene'. Rather, we are likely to be looking at the combined effects of several polymorphisms, probably in several different combinations, interacting with their environment and eventually precipitating a final common pathway of hypertension and proteinuria.
Several recent reviews have considered the current state of knowledge of the genetics of PE (eg, Morgan and Ward, 1999 20 ; Broughton Pipkin, 1999 21 ). In brief, there is some evidence for maternal-fetal sharing of a recessive gene(s), but a polymorphism in a dominant gene with partial penetrance may also be implicated. Paternal genes could contribute to the disease. 22 Such studies are becoming possible with the increasing number of women conceiving by more than one partner. Women who became pregnant by a partner who had fathered a pre-eclamptic pregnancy in another woman had nearly twice the predicted risk of themselves having a pre-eclamptic pregnancy. There is also, of course, the possibility that the development of PE is partly determined by a polymorphism in a paternally-imprinted, maternally-active gene which must be expressed by the fetus. 23 Perhaps there is a threshold for either a necessary or a susceptibility locus affected by fetal or other environmental influences which may dictate who develops the disease.
Several genetically-mediated thrombophilias have been identified at higher incidence in women with obstetric complications, including PE. 24 Two of the major genes concerned are those for 5,10-methylenetetrahydrofolate reductase (MTHFR) and Factor V. A common mutation of the MTHFR gene (C677T) is associated with increased plasma homocysteine concentrations. Raised plasma homocysteine is associated with increased lipid peroxidation, plasma triglycerides, and serum uric acid, as well as with blunted endothelial-dependent vasorelaxation and an altered phenotype of endothelium from anticoagulant to procoagulant. All these are features of PE. Three studies, of women of mixed parity, one Japanese, one Jewish and one Italian suggested an increased incidence of C677T in women with PE but this was not confirmed in a study of white, nulliparous women in Pittsburgh. 25 In the Japanese study, TT homozygosity was present in 30% of PE patients but only 11% of controls, but in the Pittsburgh study the proportions were 15% and 11% respectively. It is worth noting that, as with many other mutations, the mutant allele frequency varies widely by population (see Table 2 ). Some 2-7% of the population carry the G1691A mutation (Leiden) of the Factor V gene, which results in the substitution of glutamine for arginine, making Factor V resistant to activated protein C. Resistance to activated protein C is present in about one-fifth of women with pre-eclampsia 32 and some twice as many women with PE have the Factor V Leiden mutation as do normotensive women. 33 Thus, polymorphisms associated with clotting disorders may be predisposers for PE, but are evidently not pre-requisites.
Tumour necrosis factor ␣ (TNF␣) is a potent proinflammatory cytokine. TNF␣ mRNA expression is significantly higher in leukocytes from pre-eclamptic women. 34 The high expression of TNF␣ may be associated with the TNF1 allele, since the frequency of this allele is markedly increased in pre-eclampsia. Furthermore, the common TNF␣ polymorphism at −308 in the promoter region has been reported as being associated both with raised TNF␣ mRNA and with PE. 34 Concentrations of the soluble receptor for TNF␣ (TNF␣ receptor 1; sTNFp55) are also reportedly raised in pre-eclampsia before the clinical onset of the disease. 35, 36 However, the frequency of the TNF T2 mutation in the promoter region (the only polymorphism so far studied in this context) is not increased in either pre-eclampsia or HELLP. 37 Another promising candidate gene appears to be the angiotensinogen gene. In the first published study of pre-eclamptic patients, 38 the variant M235T was found in significantly increased frequency in women with PE, in association with a raised plasma angiotensinogen concentration. Similar findings were reported in a case-control study of Japanese patients. However, this variant has also been reported in higher frequency in non-pregnant patients with essential hypertension (see : Caulfield et al, 1996 39 ) and coronary artery disease, 40 again in association with raised angiotensinogen concentrations. This must give rise to concern about the possibility of underlying chronic hypertension in a proportion of these pregnant women (see: 'Heterogeneity of study groups' above). Furthermore, recent studies in Caucasian British, Caucasian Australian, Caucasian North American, African-American and Chinese populations have found no evidence for any increased frequency of the M235T variant in carefully-characterised pre-eclamptic women compared with normotensive pregnant controls (eg, Morgan et al, 1995 41 ; Guo et al, 1997 42 ). Furthermore, in a UK population studied during, rather than after, pregnancy, plasma angiotensinogen concentrations were actually lower in the TT homozygotes. 43 The M235T mutation is in partial positive linkage disequilibrium with a dinucleotide repeat polymorphism at the 3Ј end of the gene. This is a very polymorphic site, which therefore allows tracking of allele transmission from mother to fetus. We have recently reported a significantly increased maternal-fetal transmission of the A9 allele, which is associated with low plasma angiotensinogen concentrations, in PE. 43 A very recent study has shown that women with PE develop stimulatory autoantibodies against the angiotensin AT1 receptor. 44 The only study to date investigating possible linkage between AT1 receptor genotype and the development of PE found no evidence that the three known polymorphisms in the gene were associated with pre-eclampsia. 45 However, there is a dinucleotide repeat polymorphism in the 3Ј flanking region of the AT 1 receptor gene, and a marked distortion of maternal-fetal transmission of one of these alleles was shown in PE. 45 This allele is in partial linkage disequilibrium with the C573T variant, which in normotensive pregnancy is associated with higher levels of platelet AT 1 receptors. 45 An enhanced pressor response to angiotensin II antedates the onset of clinicallydetectable disease by many weeks. 46 These observations may therefore be of functional significance.
It may perhaps also be relevant in this context, that one of the 'best' animal models of PE so far developed involves the renin-angiotensin system. Female transgenic mice carrying the human angiotensinogen gene were mated with males carrying the renin gene. The females developed hypertension from about two-thirds of the way through gestation, with much increased urinary protein excretion Sixty percent of the mice died during pregnancy, but in those which survived, the blood pressure had returned to normal by 3 days after delivery. At autopsy, (paternally-derived) human renin was localised to the chorionic trophoblasts. Other wildtype/transgenic and transgenic/transgenic crosses were not associated with the development of 'preeclampsia'. 47 The relationship of dyslipidaemias to pre-eclampsia is emphasised by the recent finding that polymorphisms of the lipoprotein-lipase gene are five times as common in women with well defined preeclampsia as primiparas. Nearly 20% of these women carried either the N291S or the D9N/-93G to T allele combination compared to 5% of controls. 48 These polymorphisms are associated with increased plasma triacylglycerol and decreased high-density lipoprotein cholesterol concentrations. 49 Mitochondrial DNA (mtDNA) encodes essential subunits of the respiratory chain. It is critical for oxidative phosphorylation and the production of cellular energy stores in the form of ATP. Mitochondria are the major users of molecular oxygen within cells, and so are also among the most important generators of reactive oxygen species. Furthermore, mitochondria are enriched with polyunsaturated fatty acids, and are therefore very susceptible to damage by 709 lipid peroxidation. Over the last 10 years, a group of inborn errors of metabolism have been identified in which there is a failure in aerobic energy production, considered to be due to mitochondrial dysfunction. More than 50 mtDNA mutations and several nuclear gene mutations have been identified in association with specific disease states. A common 4977-bp deletion affects genes encoding seven polypeptide components of the mitochondrial respiratory chain, and five of the 22 tRNAs necessary for mitochondrial protein synthesis. Neither this nor the 7436-bp deletion have been identified in samples of PE mitochondria, 50, 51 nor have any of the three most common mtDNA mutations been found 51 (see also: Mitochondrial function below).
Candidate genes considered, and on available evidence put aside, include those for renin, angiotensin-converting enzyme, endothelial nitric oxide synthetase and superoxide dismutase. Although the human leukocyte antigen (HLA) system has been implicated, many of the findings reported have been inconsistent or contradictory. 52 
Future research in genetics:
The search for candidate genes has so far been conducted on small samples with varying stringency in phenotyping. The future has to lie in the accumulation of large samples, at the least from mother, father and newborn, which can be used for model-free analyses such as transmission disequilibrium testing. This is made possible by the recent rapid advances in genotyping technology, which will allow genome-wide scanning and the identification of 'hot spots'. That, of course, is only one step, but a very important one. Such a study, sampling from mother, father, newborn and mother's parents, has recently been funded by the British Heart Foundation as a 10-centre collaboration in the United Kingdom (the GOPEC study); recruitment will begin in early 2000.
Endothelial dysfunction in pre-eclampsia
The woman with PE manifests a diverse array of pathophysiological changes. 53 These include profound abnormalities of hepatic, renal and cerebral function accompanied by activation of the coagulation cascade. Many of these changes can be explained by reduced organ perfusion, but the profoundly disordered physiology of the woman with PE makes it impossible to separate cause and effect. A better insight into the sequence of pathophysiological changes comes from attention to those changes that antedate clinically evident PE. Activation of the coagulation cascade, especially alterations in platelet function, can be demonstrated weeks to months before clinically evident disease. 54, 55 Similarly, increased sensitivity to angiotensin 46 and reduced plasma volume 56 have been found in groups of women destined to develop PE. It is important to point out that these changes are not universally present and thus can only be recognised in groups of women destined to develop PE. Overlap of the values of normal and pre-eclamptic women is such that the available markers are not valuable as predictors. Nonetheless, these changes provide
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clues to a unifying target in PE. Increased sensitivity to pressors, platelet activation and loss of fluid from the intravascular volume could all be explained by altered endothelial cell function.
Endothelial cells, once considered as merely forming a barrier to prevent the contact of vascular smooth muscle and collagen with intravascular contents, are now recognised as subserving sophisticated functions maintaining vascular homeostasis. 57 These functions are pertinent to pregnancy and PE. Thus, normal endothelium produces factors that buffer the contractile response of subjacent vascular smooth muscle to circulating pressors. The endothelial products, nitric oxide and prostacyclin, have such vasodilator effects but in addition inhibit platelet aggregation. Other molecules produced by endothelium are responsible for the generation of normal anticoagulants. Additionally, vascular endothelium maintains normal intravascular volume by several mechanisms in addition to the obvious barrier function.
In normal pregnancy vascular volume is expanded and cardiac output increased yet blood pressure is reduced. In addition, sensitivity to angiotensin is reduced. 58 The differences in vascular response can be demonstrated in controlled in vitro settings in small myometrial resistance vessels 59 and omental vessels. 60 They are largely eliminated by removal of endothelium 59 although little or no difference has been reported in other resistance arteries. 61 This has led to the concept that at least a portion of the cardiovascular adaptations of normal pregnancy is secondary to modifications of endothelial function, in some vascular beds. The special importance of endothelium in normal pregnancy is further indicated by the increased frequency of endothelial diseases such as thrombotic thrombocytopaenic purpura and hemolytic uremic syndrome in association with pregnancy. 62 With injury or activation endothelial function is strikingly modified. Not only are vasodilator functions and anticoagulant functions downregulated but endothelial cells can also produce vasoconstrictors and manifest procoagulant function. From this description, increased sensitivity to pressors and activation of the coagulation cascade, the earliest pathophysiological changes of PE, are consistent with alteration of endothelial function. This has led to the hypothesis that endothelial dysfunction is a central pathophysiological feature of PE. The hypothesis also proposes that the poorly perfused placenta characteristic of PE generates factors that promote alteration of endothelial cell function. 63 Several lines of evidence support the involvement of endothelial cells in the pathogenesis of PE. 64 One of the most characteristic pathological findings in PE is the renal abnormality termed glomeruloendotheliosis. 65 This lesion consists of marked glomerular capillary swelling (often sufficient to occlude the capillary lumen), basement membrane inclusions and virtually no change in the renal epithelial podocytes. This finding not only emphasises that PE is not merely a variant of essential hypertension but supports the concept that endothelial cells are a target in the disorder. Several markers of endothelial Increased endothelin 222 Increased prevalence of antiendothelial antibodies 80 Increased thrombomodulin 223 Increased thromboxane 224 Increased cellular fibronection (cFN) concentration a 225 Increased plasminogen activation activity (PAI-1) 226 Increased soluble VCAM 227 Increased tissue plasminogen activator 228 Increased ICAM a 229
Increased E-selectin 230 Increased tissue factor 231 Increased ELAM 232 
Differences of in vitro vascular responses of vessels from pre-eclamptic women
Reduced endothelial dependent relaxation of subcutaneous vessels 233 Reduced relaxation of subcutaneous vessels to bradykinin 234 Reduced endothelial dependent relaxation of epigastric arteries 235 Impaired endothelial mediated relaxation in omental vessels 236 Reduced NO dependent relaxation of myometrial vessels 237 a Can be demonstrated prior to clinically evident pre-eclampsia.
activation can be demonstrated in women with PE (Table 3) . Most importantly, several of these are manifest weeks to months before clinically evident disease, supporting the central role of altered endothelial function. In vitro studies also provide evidence for products in the blood of pre-eclamptic women that alter endothelial function. Endothelial functions can be modified by either exposure of endothelial cells in culture or isolated blood vessels to plasma or serum from women with PE (Table 4) . With this approach several markers of endothelial injury or activation (eg, cellular fibronectin (cFN), platelet-derived growth factor (PDGF)) or endothelial functions (vasodilatation in vitro) are altered more by exposure to serum/plasma from women with PE than to serum/plasma from normal pregnant women or pre-eclamptic women after delivery. Preliminary characterisation of these factors has indi- Table 4 In vitro effects of serum/plasma from pre-eclamptic women
Effects upon cultured endothelial cells
Increased Cr51 release 238 Increased lipid uptake 239 Increased expression of PDGF ␤-chain mRNA 240 Increased prostacyclin release 241 Increased cFN release 76 Increased nitric oxide (NO) release 242 Increased nitric oxide synthase (NOS) expression 243 Reduced endothelial cell proliferation 244 Increased VCAM on cell surface 245 Increased permeability 246 
Effects on ex vivo vessels
Reduced endothelial dependent relaxation of myometrial vessels 247 cated the presence of more than one factor responsible for these activities. 66 Many of the risk factors that predispose to the functional endothelial alterations of atherosclerosis also come into play in PE. Elevated homocysteine, 67 elevated triglycerides 68 with associated small dense low-density lipoprotein (LDL), 69 and insulin resistance 70 are all associated with increased risk for both disorders. Some of these changes such as elevated homocysteine persist beyond pregnancy, yet the PE syndrome and the attendant endothelial dysfunction abate with delivery. This observation provides further evidence supporting the unique sensitivity of endothelial cells during pregnancy. An important recent observation may explain this unique sensitivity. The Oxford group examined inflammatory markers on circulating blood cells of normal pregnant and non-pregnant women, women with PE and non-pregnant women with sepsis. 71 They found striking increases in markers of inflammation in normal pregnant compared to non-pregnant women that were increased only slightly more in women with PE. The increased inflammatory response of normal pregnancy may provide at least a partial explanation for the increased sensitivity of vascular endothelium during pregnancy.
What is the factor that alters endothelial function during pregnancy? The nature of endothelial dysfunction during pregnancy may provide some insight. Endothelial dysfunction may be due to activation of usual functions in an inappropriate setting or, alternatively, physical injury of the cells. The endothelial dysfunction of PE, especially that present before the overt syndrome, is more consistent with activation than with mechanical injury. Blood concentrations of thrombomodulin, an endothelial protein only released with actual injury, are only increased with clinically evident PE. 72 By contrast, reduced prostacyclin production, 73 increased circulating von Willebrand factor 74 and growth factor activity, 75 features of endothelial activation are altered weeks to months before clinically evident PE. The relevance of in vitro effects of PE serum/plasma to the in vivo setting is open to question. With this proviso, in vitro studies do not support a generalised toxic effect of serum/plasma from women with PE. The effects are relatively selective, with some markers of activation being stimulated while others are not. Also, in most settings cells appear normal and maintain structural integrity. 76 Thus, the nature of the dysfunction would suggest that the responsible factor is not a toxin but more likely a usual factor present inappropriately or at higher than usual concentration.
Several factors have been suggested. These include cytokines, TNF␣ in particular, 77 activated neutrophils, monocytes or platelets, 78 stable products of lipid peroxidation, 79 syncytiotrophoblast fragments and antibodies. The antibodies suggested include autoantibodies to endothelial cells 80 and more specifically autoantibodies to the angiotensin (AT 1 ) receptor 44 that are capable of activating the receptor. With attention to the cautions above, preliminary characterisation of the activities that alter endothelial in vitro indicates that one of these 711 resides in the LDL fraction. 66 The question as to the identity of the responsible factor(s) is far from answered but as will be discussed below, an interesting theme present with the majority of these suggestions is a relationship to oxidative stress.
Future research on the endothelium:
The increased evidence supporting the role of endothelial dysfunction in the genesis of PE has interesting implications. Could a marker of endothelial dysfunction be used as a more specific diagnostic marker of the disorder that currently used signs? Would markers of endothelial dysfunction serve as a useful indicator successful preventive therapies? What allows change in endothelial function in some but not all vascular beds?
Lipids in pre-eclampsia
The alteration of circulating lipids is one of the more striking metabolic changes of pregnancy. Normal pregnancy is associated with an approximate threefold increase in triglycerides and fatty acids, and a 50% increase in LDL cholesterol. High-density lipoprotein (HDL) cholesterol is also increased. 81 The triglyceride, fatty acid and LDL cholesterol changes are accentuated but HDL reduced in PE. 68, 82 Changes in fatty acids and triglycerides antedate clinically evident PE. 83 It is not known if they antedate pregnancy. However, dyslipidaemia can be demonstrated to be more prevalent in later life (20 to 30 years later) in women with recurrent PE. 84 Of the lipid changes in pregnancy and PE perhaps the most surprising is a shift in the spectrum of LDL subclasses toward proportional increases in smaller, denser LDL particles. 69 The presence of the small dense LDL variant is predictable from the elevated triglycerides associated with pregnancy but is surprising from the perspective that this lipoprotein moiety is considered most pathophysiologically relevant in atherosclerosis. 85 Small dense LDL have increased access to the subendothelial space where they also reside longer than other LDL particles. In this setting, the particle is sequestered from the protective effects of circulating antioxidants. In addition, small dense LDL are inherently more easily oxidized. In atherosclerosis, this combination is proposed to lead to the formation of oxidized LDL (ox-LDL) with subsequent alterations of endothelial function. 86 Additionally, increased VCAM expression in response to ox-LDL recruits monocytes. Oxidized LDL is taken up by the monocytes with subsequent formation of foam cells and the generation of the atheromatous plaque. It is tempting to speculate that the same changes occur in PE and account for altered endothelial function. The morphological changes of atherosclerosis have not been reported in the systemic circulation of women with PE. However, decidual vessels do manifest a morphological abnormality termed atherosis. 87, 88 This alteration includes fibrinoid occlusion of the vessels that are surrounded by foam cells, changes reminiscent of atherosclerosis. Functionally, the altered endothelial responses of women with PE are similar to the blunted endothelial responses present
Journal of Human Hypertension with atherosclerosis. 89 Thus, the dyslipidaemia of PE acting through oxidative modification of susceptible lipids may contribute to the altered endothelial responses of the syndrome. If this concept is validated by future research, dyslipidaemia may serve as a target for preventive therapy either prior to or in early pregnancy.
Mitochondrial function
In 1989, Torbergsen et al 90 described carefullycharacterised mitochodrial dysfunction in a family with a high incidence of PE and eclampsia. The recent upsurge of interest in the potential rô le of lipid peroxidation and increased free radical concentration in the pathogenesis of PE (see section: Lipids in pre-eclampsia) has led to an examination of the cellular localisation in the placenta of proteins specifically modified by lipid peroxidation. While not all placentae from PE pregnancies show evidence of peroxidation in the trophoblast, where such modified proteins are identified, they can be localised in the mitochondria. 91 Malonyldialdehyde concentrations are a crude marker of lipid peroxidation; such concentrations were significantly higher in mitochondrial fractions from placentae from PE than from normotensive pregnancies. 92 Mitochondrial fractions from PE placentae were also associated with greater stimulation of lipid peroxidation by such agents as NADPH. 
Maternal-fetal interactions: insulin resistance and the maternal syndrome
Implicit to the understanding of PE is the concept that the disorder is a two-stage disease. The abnormalities of placentation described below and the risk factors for PE that would be associated with reduced placental perfusion (Table 5 ) implicate a compromised blood supply to the placenta as an integral component of the disorder. Further support for the concept comes from obstetrical risk factors for pre-eclampsia. These include the large placental mass associated with multiple gestations, hydatidiform moles and hydropic placenta that are proposed to result in a relative reduction of uterine perfusion. 93 However, it is evident that abnormal placental perfusion (Stage 1) is not sufficient to explain the maternal systemic syndrome (Stage 2) of PE. Many growth restricted infants (IUGR) that must have received inadequate placental blood flow come from pregnancies that are not complicated by PE. Even more strikingly, the abnormal placentation characteristic of PE is also present in the implantation sites of pregnancies complicated by IUGR and one-third of those complicated by preterm birth. 94, 95 This has stimulated the hypothesis that the abnormal perfusion must interact with maternal constitutional factors to generate the maternal syndrome. 96 What are these maternal predispositions? Table 5 lists risk factors for PE. Note that whereas some of these factors could relate to PE by effects on placental perfusion, for many this relationship seems unlikely.
However, most of these are associated with insulin resistance and/or the 'metabolic syndrome'. 97 This syndrome has been described as associated with increased cardiovascular risk and includes obesity, dyslipidaemia, hypertension, insulin resistance and, interestingly, elevated plasma uric acid concentrations. How this constellation of abnormality relates to cardiovascular disease is not clearly established. There is evidence of reduced endothelial mediated vasodilatation with the syndrome. 98 The postulated effects of the dyslipidaemia are discussed above and the mechanisms of elevated blood pressure to generate cardiovascular disease are well established. However, direct contributions of insulin resistance or the accompanying hyperinsulinaemia are not clear. Also, where the circle begins is also open to question. For example, insulin resistance will result in increased free fatty acids while free fatty acids increase insulin resistance. 99 Regardless of mechanisms, abnormalities that are components of the metabolic syndrome are associated with and likely predispose to PE. 100 Pre-pregnancy obesity has a dose response relationship to PE. 101 As obesity increases so does the risk of PE. Increased androgens are present in women with PE and women with a history of PE. 102, 103 The dyslipidaemia of PE is identical to that present in the syndrome. It seems likely that these changes in a more subtle form antedate pregnancy. Alterations of fatty acids and triglycerides are present from early pregnancy 83 and women with PE are five times as likely to have function perturbing mutations of the lipoprotein lipase gene. 104 Women with PE have increased circulating insulin, 105 and PE is more common in women with gestational diabetes. 106 Using 'minimal model' analysis of response to intravenous glucose, insulin resistance was increased in women with PE. 107 The likelihood that this change may have antedated pregnancy was indicated by the persistence of increased insulin resistance for 12 weeks post-partum. Similarly, women re-examined more than 10 years after a pre-eclamptic pregnancy had higher fasting insulin concentration. 108 The metabolic syndrome is associated with increased risk of cardiovascular disease. However, the classic studies of Chesley have been interpreted to indicate that with well defined PE there is no increased risk of cardiovascular disease in later life. 109 It is important to point out that although the women in the control group of Chesley's studies were matched for factors that might influence cardiovascular disease and hypertension (age, race, socio-economic status), their pregnancy history was unknown. In a smaller study it was evident that women who had pregnancies that were not complicated by PE had a lower risk of cardiovascular disease than the unselected female population. 13 This would suggest common risk factors for PE and cardiovascular disease. This is further supported by other risk factors for PE that are not part of the metabolic syndrome. Elevated homocysteine 67, 110 and black race 111 are associated with increased risks of both conditions.
Future research
The number of genetic, environmental and behavioural factors that predispose to the metabolic syndrome could provide targets for prepregnancy therapy. This diversity of factors also emphasises the heterogeneous nature of predisposing factors for pre-eclampsia.
Oxidative stress as the linkage for the two stages of PE
Oxidative stress, an excess of free radicals and reactive oxygen species over antioxidant scavengers, has been implicated in several disease states including atherosclerosis. The formation of these reactive species results in alterations of cellular function with endothelium particularly vulnerable. The similarities between atherosclerosis and PE, the suggested role of oxidative stress in the metabolic syndrome and the involvement of oxidative stress in the activities of many of the agents proposed to alter endothelial function in PE, stimulate the hypothesis that oxidative stress may provide the linkage between the two stages of PE. 112 There is abundant evidence that oxidative stress is increased in PE. There are increased concentrations of stable metabolites of the reactive lipid peroxides, malondialdehyde and isoprostanes in blood and tissues. 79 In addition, plasma from women with PE oxidizes ascorbic acid in vitro. Not surprisingly, circulating concentrations of this lynchpin antioxidant are reduced in women with PE, likely indicating consumption in vivo. 113 What is the source of free radicals? A prime mechanism for the generation of free radicals is the hypoxia reperfusion phenomenon. 114, 115 In this scenario, oxygen delivery to a tissue is reduced such that ATP can no longer be oxidized and is metabolised to adenine. The bifunctional enzyme xanthine oxidase dehydrogenase increases in response to hypoxia and is preferentially converted to its oxidase form. In the dehydrogenase form the enzyme catalyzes the conversion of purines including the increased content of adenine to NADH and uric acid. By contrast, the products of the xanthine oxidase form of the enzyme are the superoxide radical, hydrogen peroxide, and uric acid. Superoxide and hydrogen peroxide are buffered by available antioxidants until they are consumed. The consequences of the generation of free radicals and antioxidant consumption is a second wave of tissue injury when oxygen is restored to the previously hypoxic tissue. The intervillous space would seem to be particularly 713 vulnerable to this process. The blood flow of the uterus varies widely with daily activities and intervillous blood flow is directly reduced by myometrial contractions. Nonetheless, the variations of blood flow are usually well tolerated indicating the presence of protective homeostatic mechanisms. For example, the concentration of xanthine oxidase dehydrogenase is very low in the placenta. 116 It is possible, however, that in a setting of reduced placental perfusion, as is characteristic of PE, these mechanisms may be overcome and oxidative stress ensue. Support for this speculation is the demonstration of increased xanthine oxidase mass and activity in the invasive cytotrophoblasts of women with PE. 117 Another potential source of free radical generation is elevated free iron which may be present in PE. Free iron can catalyse free radical production and lipid peroxidation. 118 Local formation of free radicals in the intervillous space or decidua could be transmitted to endothelium by several of the suggested mediators of endothelial activation in PE. Stable products of lipid peroxidation such as MDA are themselves capable of oxidant activity. Also, neutrophils and other blood elements activated by exposure to oxidative stress in the intervillous space could release reactive oxygen species on contact with endothelium. The role of placental fragments may also relate to local oxidative stress. There is evidence that villous membranes are oxidatively modified in PE 119 and fragments of these modified tissue could induce distant endothelial oxidative modification. The altered membrane fluidity of these membranes would favour their shedding, as would apoptosis known to be induced by oxidative stress. 120 Likewise, activation of the angiotensin II receptor by autoantibodies could result in activation of the enzyme NADH/NADPH-oxidase with the generation of reactive oxygen species. 121 The consequences of the generation of free radicals will be influenced by maternal factors including antioxidant capability, the presence of other promoters of oxidative stress (eg, homocysteine) and the presence of susceptible substrate such as small dense LDL. Thus, oxidative stress provides a plausible linkage between reduced placental perfusion and endothelial dysfunction that is influenced by maternal factors. This hypothesis was directly tested in a recent trial of antioxidant therapy. 122 The investigators proposed that treating women at risk for PE with antioxidant dosages of vitamin E and C from 22 weeks' gestation would reduce evidence of endothelial activation. They measured the ratio of plasminogen activator I (made by activated endothelial cells) to plasminogen activator II (made by the placenta) as a marker of endothelial activation. They reported that antioxidant therapy was associated with a 21% reduction in the ratio, consistent with reduced endothelial activation. Surprisingly, there was also a significant reduction in the incidence of PE in this small (140 in each group) study. These findings are quite interesting and support the role of oxidative stress in the genesis of endothelial activation in PE. However, before the exciting possibility that this therapy prevents PE moves to clinical Journal of Human Hypertension practice, the effectiveness and even more importantly fetal safety, must be proven in larger studies.
The cardiovascular system
It is increasingly apparent that many of the cardiovascular adaptations to normal pregnancy are initiated in the luteal phase of every menstrual cycle, and are merely amplified should conception occur. For example, careful prospective studies of ovulatory cycles show significant falls in mean arterial pressure (MAP) and total peripheral resistance (TPR) in the mid-luteal phase, with a rise in heart rate (HR), cardiac output (CO), renal plasma flow (RPF) and glomerular filtration rate (GFR) ( ). These changes are all amplified should conception occur. They are thus proactive, not reactive.
The TPR has been reported as being significantly decreased by at least 6 weeks gestation age, 130 by which time CO has also risen, 130, 131 through increases in both stroke volume (SV) and HR. It may be that the first response to pregnancy is the fall in vascular resistance. This in turn would cause a relative 'underfilling', associated with a fall in arterial blood pressure and concomittent increase in HR and SV. The raised circulating concentrations of plasma renin concentration, plasma renin activity, AII and aldosterone (ALD) in the luteal phase of the cycle do not fall, but continue to rise should conception occur (Sundsfjord and Aakvaag, 1973 132 ; Chapman et al, 1998 130 ). The RAS is thus one of the earliest hormone systems to 'recognise' pregnancy, and may well be being activated as a response to the perceived underfilling.
If, as seems more and more likely, PE is initiated by a failure of adaptation to pregnancy, then one might expect to see very early differences in women who go on to develop PE. This, however, requires very large-scale prospective studies throughout pregnancy, beginning, preferably, before conception. Such pre-conception studies have not been done, but two prospective studies of nulliparae have been reported. Easterling et al (1990) 133 reported a longitudinal study of 179 women, from whom serial measurements of blood pressure, CO (Doppler) and derived TPR were made from at least 22 weeks gestation. Nine were described as having developed PE. Unfortunately, the definition of PE used required only the presence of 1+ protein or more which is now not considered to be sufficiently stringent (see: Definitions and Brown and Buddle, 1995 134 ); only two of their patients would be classified today as having PE. With this caveat, the data are, however, interesting, in that they show a relatively raised CO and MAP from late in the first trimester in women who went on to develop a raised blood pressure with non-significant proteinuria. The TPR in these women was slightly but not significantly lower than in those who remained normotensive. A prospective study of 400 nulliparae, using the more stringent definition, has also recently reported a raised CO and unchanged TPR prior to the onset of clinical PE, 135 with a progressive fall in CO and rise in TPR as the disease became manifest. Interestingly, those who developed GH only retained a relatively raised CO until delivery. In established PE, CO has been measured by Swan-Ganz thermodilution immediately prior to the initiation of therapy and shown to be significantly lower, and TPR higher, than in normotensive controls 136 . Thus, in the first trimester, a proportion of nulliparae show a hyperdynamic circulatory response (future GH), with a later switch in a small proportion of patients (future PE) in response to an as yet unknown stimulus. The total blood and plasma volumes are both reduced in established PE, with a smaller fall in both in GH;
137,138 the timing of this volume contraction has not been established. Interestingly, in PE the total extracellular fluid volume (ECFV) is unchanged, so that the ratio of plasma volume: ECFV is significantly reduced compared with normal pregnancy, 137 presumably in association with a 'leaky' circulation. 139 There is a small fall in systolic, and a greater fall in diastolic blood pressure during the first half of pregnancy in both normal and future hypertensive women (eg, Christianson, 1976 140 ; Halligan et al, 1993 141 ). It is important that the blood pressure be recorded at the first antenatal clinic visit to give the base against which subsequent change can be assessed (see: Definitions). The blood pressure rises steadily thereafter, in both normal and future hypertensive women, but the rate and amplitude of the rise is accelerated in women who develop GH or PE. Longitudinal studies in primigravid pregnancy have shown that women who go on to develop GH or PE have relatively raised blood pressures at the first antenatal clinic visit, but since these are still well within the normotensive range, and the overlap is considerable, this has a low specificity in predicting women at risk (eg, Massé et al, 1993 142,143 ). Normotensive pregnancy is associated with a progressive venodilatation. 146 There are changes in venous distensibility and capacitance, to accommodate the increased flow on the venous side, both distensibility 147 and capacitance being higher in the normal pregnant than in the non-pregnant woman. In non-pregnant women, venous capacitance is greater in the leg than in the forearm, but in pregnancy, this difference is lost, presumably because of the haemodynamic effect of the gravid uterus. 144 Women with GH have significantly-raised forearm venous tone by comparison with normal pregnant women, 148 but interestingly, a prospective study showed this to be preceded by a period of increased venodilatation. 146 When the central blood volume in such women was increased by a period of passive leg elevation, the women with GH showed venodilatation, unlike normal pregnant women or non-pregnant women, who showed no change. 148 Furthermore, forearm blood flow in women with GH or PE was either unchanged 144 or somewhat increased. 145, 149 This suggests that the abnormalities of tone found in established disease represent homeostatic, rather than primary pathological, mechanisms. Women with severe PE have reduced venous distensibility antepartum, but are indistinguishable after delivery from women who were normotensive during pregnancy. 147 Their forearm vascular resistance and tone are higher than those recorded in women with GH. 150 What factors might be driving these changes? Ambulatory blood pressure monitoring shows that in normal pregnant women, as in the non-pregnant state, the blood pressure falls at night, but in women with PE, this fall is blunted, 151 and even reversed in ෂ20%. 152 The HR variability is decreased in normal pregnancy 153, 154 in the face of a normal increase of 10-15 beats/min. The baroreflex sensitivity, the linkage between changing arterial pressure and HR, has not been intensively studied in pregnancy, and data available are conflicting. An increased baroreflex sensitivity during normal pregnancy was reported in earlier studies, 155, 156 the inference being that the lower blood pressure of pregnancy is 'perceived' as normal, and that the baroreceptors have been reset. However, in subsequent studies using cross-spectral analysis and non-invasive blood pressure monitoring, a decrease in baroreflex sensitivity has been reported from the second trimester of normal pregnancy, 154 and in the third trimester by comparison with non-pregnant women 157 or with the same subjects post-partum. 158 The changing cardiovascular response to head-up tilt as pregnancy progresses also suggests a fall in baroreflex sensitivity. 159 A further decrease in baroreflex sensitivity has been reported in PE. 157, 160 Indeed, Wasserstrum et al (1989) 160 reported that: 'In patients with higher baseline blood pressures, the severe impairment of baroreflex function eliminated the normal circulatory buffer against vasodilator-induced hypotension', presumably accounting for the profound falls in blood pressure which can be seen in such patients during the administration of hydrallazine.
On the assumption that the fall in blood pressure initially, and the subsequent rise, accelerated in GH and PE represented changing sympathetic tone, Assali et al (1952) 161 examined the effect of ganglion blockade with TEAC. To their surprise, the administration of TEAC was associated with greater falls in BP in pregnant than non-pregnant women. This enhanced response returned to non-pregnant levels during the third trimester. This suggested activation of the sympathetic nervous system, presumably in response to some (hormonal?) vasodilator stimulus. Vasodilator hormone synthesis and excretion is certainly markedly enhanced from early in normal pregnancy, presumably to facilitate expansion of the plasma and blood volumes. For example, the urinary excretion of prostaglandin 6-keto F 1␣ is significantly increased by the end of the first trimester 73 while the excretion of kallikrein is increased from at least 16 weeks gestation. 162 The local generation of nitric oxide (NO) may also be involved; there is increased NO activity in the veins of the dorsum of the hand in pregnancy. 163 Blood flow itself is a major regulator of endothelial NO synthesis, and Cockell et al (1997) 164 have shown in small arteries from fat biopsies in healthy pregnant women that NO responses to flow are enhanced by comparison with those from non-pregnant subjects. Furthermore, the forearm vascular response to NO synthase inhibition is enhanced in normal pregnancy by comparison with non-pregnant women, also suggesting a rô le for NO in the vasodilatation of pregnancy. 145 Might pressor responsiveness to vasoconstrictors be reduced? Normal pregnancy is indeed associated with a decrease in the pressor response to AII, first described nearly 40 years ago. 165 However, this is specific to AII, and is not due to a generalised decrease in vascular responsiveness, as the response to noradrenaline has been repeatedly described as being unchanged. [166] [167] [168] [169] The pressor responsiveness to AII returns to non-pregnant levels in late gestation 46 in parallel with the rise in blood pressure. The pressor response to AII is mediated via the type AT1 receptors. When platelets have been used as models of vascular smooth muscle, decreased AII binding has been shown from early in the first trimester, 170 which may result in the decrease in pressor response. Again, this change begins to return to nonpregnant levels in the second half of gestation. The fall in platelet AII binding has also been observed in the second half of the menstrual cycle, 171 and is therefore another proactive change, preparing for pregnancy.
Assali et al (1952) 161 also studied the effect of TEAC in women with 'PE', and showed it to have a lesser effect, suggesting that there was withdrawal, not activation, of sympathetic tone in these women. Differing results have, however, been reported recently, using power spectral analysis. This showed a pronounced increase in power in the very low-frequency range of heart rate variability, suggesting a marked increase in sympathetic tone. 172 The urinary excretion of both prostaglandin 6-keto F 1␣ and kallikrein is reduced long before clinical signs of the disease are apparent (eg, Fitzgerald et al, 1987 73 ; Millar et al, 1996 162 ; Mills et al, 1999 173 ), perhaps again reflecting early endothelial damage. There is considerable interest in the possibility of decreased endothelial NO synthesis contributing to the vasoconstriction of PE. Adequately diet-controlled studies of (nitrite+nitrate) excretion have yet to be performed in women with PE, although a study of plasma concentrations after one day of dietary control reported higher levels than in normotensive pregnant women. 174 Anumba et al (1999) 145 reported no difference in response to inhibition of NO synthase between normal and pre-eclamptic pregnant women. The surrogate measurement of cGMP will also reflect plasma concentrations of atrial natriuretic peptide, 175 which have also been reported to be higher in PE (eg, Thomsen et al, 1987 176 ; Irons et al, 1997 177 ). Indeed, one report suggests that a rise in plasma ANP antedates the clinical diagnosis of PE. 178 Thus two major vasodilatatory systems seem to have enhanced activity in hypertensive pregnancy, presumably as a secondary response to the raised pressure.
Women who have become hypertensive in preg-
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nancy have an enhanced pressor response to AII (eg, Talledo et al, 1968) ; 179 this is foreshadowed by a more rapid rise in pressor response to AII from at least the second half of pregnancy in such women 46 and paralleled by increased platelet AII binding. 180, 181 However, in women with established GH or PE, the pressor response to other agonists is also enhanced, implying a general underlying dysfunction. A probable early mechanism for this has been described above (see: Endothelial dysfunction in pre-eclampsia). However, there is also a later contributory factor, in the shape of increased smooth muscle intracellular free calcium concentrations, which is seen in established PE but not in GH. 182 The mechanism for this has not been elucidated, but there are known abnormalities in renal calcium handling in PE (see below: Renal function).
Future research in the cardiovascular system: The available observations suggest that at least some of the cardiovascular changes of PE are initiated during the first months of pregnancy. A main aim of future research must therefore be the study of very early pregnancy, preferably including pre-conception data. Such data are very time-consuming to collect, but are invaluable as a resource. Non-invasive methods of measuring cardiac output, blood pressure, blood flow and baroreflex sensitivity are now available, and may be used in sequential studies. The reported changes in baroreflex sensitivity in normal and hypertensive pregnancy have not been considered in the light of mechanisms. In such studies attention should be directed to the variance of the data. It is quite likely that not all women, for example, will manifest increased cardiac output or altered baroreceptor response and that any cardiovascular change could be a predisposing factor to other more universal pathogenetic mechanisms.
There is increasing awareness of similarities between insulin resistance and some features of established PE (see above: Maternal fetal interactions: insulin resistance and the maternal syndrome).These features may persist for at least 3 months after pregnancy, 70, 107 with potentially detrimental effects on future health. This is an emerging area of research with potentially wide-reaching consequences. Indeed, from the point of view of the well-being of the individual patient, long-term follow-up studies should also be initiated, not only of the mother, but also of her baby.
Renal function
'Glomerular endotheliosis' is unique to PE, and resolves post-partum. 65 There is glomerular hypertrophy, with swelling of the glomerular endothelium and increased glomerular wall thickness. The glomerular tufts appear obstructed, with narrowing of the glomerular capillary loops (see: Conrad and Lindheimer, 1998 183 ). Lipid droplets may be present in the cytoplasm ('foam cells') and there may be fibrin deposition.
On the basis of available evidence, it appears likely that the undoubted changes in renal function in PE are secondary, rather than primary. Thus, there is not a major research effort being devoted to the topic at present. There is an excellent recent review of renal function in PE, 183 to which the interested reader is referred. In summary, in established PE the GFR is reduced by one-third, with a smaller percentage fall in effective RPF; the filtration fraction thus falls. These changes can completely wipe out the normal increases in renal function during pregnancy, as shown by studies of the same women before and after delivery. The reduced RPF is still demonstrable 4 months post-partum, as is a contracted plasma volume. 184 The renal clearance of uric acid is reduced in established PE, resulting in hyperuricaemia, the degree of which varies directly with severity of disease. There appears to be an increased net reabsorbtion of uric acid which, together with the lower GFR, will result in lower renal clearance. The most likely explanation for the altered renal handling lies in the volume contraction of PE (see above).
The normal pregnant woman retains some 950 mmol sodium in the course of pregnancy. AII is antinatriuretic in physiological concentrations, but from as early as the first trimester, this effect is blunted, 185 in parallel with the decreased pressor response to the hormone. Interestingly however, the adrenal responsiveness to AII is maintained. A prospective study reported that, prior to 32 weeks gestation, no difference could be demonstrated in the association between urinary sodium excretion and arterial pressure in women who remained normotensive and those who became hypertensive. 186 The excretion of a sodium load does not differ significantly between non-pregnant and normotensive pregnant women in the second trimester, but in the third trimester, there is a tendency to sodium retention and expansion of plasma volume under these circumstances. 187 These authors reported that in a prospective study of salt loading in second trimester primigravidae, those who went on to develop GH did not handle a sodium load differently from those who remained normotensive. However, once PE was established, they retained sodium avidly, with a reduction in filtered sodium. 187 Normal pregnant women have a raised ALD:PRC ratio by comparison with non-pregnant women, and in established GH, the ratio is still further raised, 188 suggesting an altered adrenal responsiveness to the RAS. An enhanced natriuretic response to ANP has been described in PE, 177 which, in conjunction with the increased circulating concentrations, might contribute to the volume contraction.
One of the pathognomic features of PE is the development of significant proteinuria (see: Definition). Serum albumin concentrations fall in normal pregnancy, as a consequence of plasma volume expansion outstripping albumin synthesis. Urinary albumin excretion is significantly increased in normal women by 16 weeks gestation, and takes up to 3 months to return to pre-conception values. 189 Massé et al (1993) 142 studied urinary microalbumin excretion measured prospectively in more than 1300 nulliparas and reported that it was already significantly higher between 15-24 weeks gestation in women who went on to develop GH or PE. The fall in serum albumin is enhanced in PE, and concentrations may reach values as low as 20 g/l. The overall pattern of change in serum proteins resembles that found in the nephrotic syndrome, 190 and is a type of acute phase response. An increase in intraglomerular pressure would result in increased filtration of intermediate-sized molecules, such as has been reported in PE; such an effect can be mimicked by the infusion of AII. 191 It is of interest that the urinary albumin excretion rate remains high up to 3-5 years after delivery following PE. 192, 193 It is not known whether this is a long-term consequence of the pregnancy disease or whether a degree of vascular disease was present before conception.
Urinary calcium excretion is two-to three-fold higher in normal pregnancy than in the non-pregnant state, even though there is a need to conserve calcium for both maternal and fetal development. There is however, an increase in the concentrations of 1,25-dihydroxy vitamin D and a reciprocal fall in intact parathyroid hormone levels. The increase in serum 1,25-dihydroxy vitamin D values is probably a key factor in providing for these increased calcium requirements in pregnancy. 194 Changes in calcium metabolism are well-recognised in essential hypertension. Hypocalciuria is common in established PE (eg, Taufield et al, 1987 195 ; Sanchez- Ramos et al, 1991 196 ). Furthermore, the mean urinary calcium:-creatinine ratio is decreased from the first trimester in women who go on to develop PE, 197 although the overlap with women who remain normotensive is considerable, and measurement of the ratio is not helpful as a predictor of outcome. 198, 199 The mechanism for the hypocalciuria of PE has not been fully worked-out. Women with established PE have decreased plasma 1,25-dihydroxy vitamin D concentrations and increased plasma parathyroid hormone concentrations. 200, 201 The lower 1,25-dihydroxy vitamin D concentrations could be due to diminished renal or placental hormone synthesis, and would be expected to decrease intestinal calcium absorption. Serum ionised calcium is lower in established PE, 200, 201 but intracellular free calcium concentrations are increased, for example in the platelets. 182 Given the impact of intracellular calcium concentrations on vascular reactivity, it is perhaps surprising that more research has not been carried out in this area.
Placentation
Human placentation involves an intensely invasive process, in the course of which there is major remodelling of the resistance vessels of the uterine circulation. In a normal pregnancy, the cytotrophoblasts (epithelial stem cells from future placental tissue) invade the spiral arterioles and progressively erode their walls until they are structurally floppy, thin-walled conduits (See: Robertson et al, 1984 202 ), with the capacity to support a greatly enhanced blood flow. This erosion continues beyond the deciduo-myometrial junction, and the arteriolar structure is never regained after pregnancy. Indeed, it is never regained once a pregnancy has progressed beyond 14 -16 weeks of gestation, which has been 717 linked to an apparently protective effect of a midtrimester pregnancy loss in relation to PE. The maternal placental circulation is established surprisingly late, at 13-14 weeks 203, 204 so that at 8-10 weeks gestation, the oxygen pressure within the intervillous space is only about 18 mm Hg. 205 Once the placental circulation is established, the blood perfusing the cytotrophoblasts is at maternal oxygen tensions. It has thus been suggested that the cytotrophoblast invasion may be partly regulated by the prevailing oxygen tension. This has been tested by Genbachev et al (1997) , 206 using in vitro methodology, who showed that hypoxia stimulated cytotrophoblast proliferation and differentially altered the expression of some stage-specific antigens. Another proposed stimulatory mechanism concerns placental TGF-␤3 expression, which is high in early pregnancy but begins to fall at ෂ9 weeks' gestation. These changes are reciprocally correlated with trophoblast outgrowth and fibronectin synthesis, which are markers of trophoblast differentiation toward an invasive phenotype. 207 A fascinating observation has recently been reported, 208 which suggests that the invasive cytotrophoblasts may switch their repertoire of adhesion molecules to mimic the adhesion phenotype of endothelial cells, with enhanced molility and invasiveness. Vascular endothelial growth factor (VEGF) has been localised immunohistochemically in normal term villous placenta in the syncytiotrophoblast with less intense staining in stromal cells 209 and is assumed to be concerned with placental angiogenesis.
One of the major pathological features of PE is the relative failure of trophoblast invasion 210, 211 , which does not proceed beyond the deciduo-myometrial junction. This is not unique to PE, but is also found in association with intra-uterine growth restriction occurring in the absence of hypertension. 212 Since flow is proportional to the fourth power of the radius, it is not surprising that a reduced spiral artery diameter is associated with fetal growth restriction. There may thus be a differential responsiveness to impaired foeto-placental blood flow in the two groups of women, but formal studies of factors mediating this differential response have yet to be performed.
Histologically, the cytotrophoblasts do not appear to be adequately 'anchored' to the vascular endothelium, and do not invade, or invade inadequately. A major difficulty in studying mechanisms for the impairment of placentation is that the diagnosis of PE is made late in pregnancy, and data gathered from histological and in vitro studies of placental tissues gathered at the end, even a premature end, of gestation, may bear little relationship to what was happening at the initiation of placentation. All that can be done is to match control and PE tissues for gestation age. Lower trophoblast attachment on fibronectin and vitronectin-coated slides was observed in samples from PE than normotensive pregnancies, possibly reflecting differences in expression of matrix receptors. 213 There was also a decreased multinuclear cell formation, indicating lesser syncytialization of trophoblast in this group. It has also been shown that the cytotrophoblastic expression of Journal of Human Hypertension the ␣V␤3 integrin characteristic of angiogenic endothelium, and enhanced in cytotrophoblasts which have invaded the spiral arteries, is weak. 214 In contrast, expression of ␣V␤6 is maintained; this is transiently expressed in remodelling endothelium and is confined to sites of column formation in normal placentae. 214 It thus appears that the invasive cytotrophoblasts from PE placentae have failed to transform their phenotype to mimic that of vascular endothelium. Furthermore, TGF-␤3 is overexpressed in placentae from PE pregnancies, leading to the suggestion that a failure to downregulate such expression in early pregnancy might contribute to the abnormal placentation. 207 The localization of VEGF in placental biopsy samples at delivery has been reported not to differ qualitatively between normal and PE placentae although the intensity of VEGF immunostaining in syncytiotrophoblast was significantly reduced in PE. 209 A 'deportation' of trophoblast to the maternal circulation has been reported in established PE. 215 Trophoblast cells were found in the uterine venous blood (but rarely in peripheral venous blood) of normal pregnant women with higher levels in preeclampsia. There was no correlation between trophoblast numbers and indices of severity of the disease, and the authors concluded that increased trophoblast deportation in PE is secondary to the changes occurring in the placenta. The medium from co-cultures of syncytiotrophoblast microvillous membranes (STBM) and endothelial cells caused significant activation of granulocytes and monocytes derived from male subjects. 216 Such an effect might account for the observed activation of peripheral blood leukocytes in PE. Furthermore, vesicles prepared from STBM reduced the relaxation response of preconstricted subcutaneous fat arteries from normotensive pregnant women to acetylcholine, presumably due to decreased endothelial dependent relaxation. 164 Thus some of the endothelial dysfunction seen in PE might be secondary to the consequences of increased trophoblast invasion.
Future research in placentation
It has to be accepted that any studies of function on tissue derived from PE pregnancies may be misleading in relation to the initiation of the disease process, which is likely to occur very early in gestation. By the time the disease is clinically-manifest, the placenta, like other tissues, has been exposed to deteriorating conditions for months. Thus, attempting to unravel cause from effect is extremely difficult. Furthermore, the placenta has a built-in obsolescence even in normal pregnancy, and is programmed to function under conditions very different from those pertaining in culture. Its enzyme systems on the fetal side function under conditions of low oxygen (ෂ25-30 mm Hg) and high carbon dioxide (ෂ50-55 mm Hg) tension; the effect of the sudden perfusion with well-oxygenated blood which occurs after the first breath, before placental separation, has not been studied, but is likely to be large. Intrinsic placental coagulation systems are also rapidly activated at placental separation.
Our knowledge of the processes of normal placentation is still only partial, and hindered by the fact that when samples are obtained in early human pregnancy, the majority of such pregnancies will not proceed to term. Nevertheless, further studies of normal placentation are likely also to be of help in unravelling the pathophysiology of PE. Research into the expression and function of the ever-increasing family of growth factors in relation to placentation is likely to burgeon. Data at present are not entirely consistent, and it may well be that, in a process as vital as placentation, there are a number of 'safety nets', such that more than one cytokine can exert a particular effect.
For the future?
We have to accept that, unlike many disease states, there is still no adequate animal model for PE. Given the apparently central rô le of placentation in the disease, and the enormously variable nature of placentation in the Mammalia, this should not cause surprise. Certainly, hypertension can be induced in pregnant animals, and the consequences of that hypertension examined, but that is not the same as having a naturally-occurring animal model. Sheep 'toxaemia' is a disorder of carbohydrate metabolism. Although there is developing interest in insulin resistance as a predisposing factor for PE, one feels that human PE is unlikely to respond to the oral administration of calcium borogluconate, which, as shepherds are well aware, is the remedy in sheep.
The long-running searches for a predictor or predictive index for PE, and, in parallel, for an adequate prophylactic regime, are likely to continue until we identify the causes of PE and can therefore apply more logic to the quest. The literature is littered with attempts to derive predictive indices, some on small, very tightly-controlled, data sets, other on much larger sets, genuinely attempting to identify predictors in the frenetic activity of an antenatal clinic. These have recently been reviewed. 217 As for prophylaxis, very large-scale trials have shown that low dose aspirin does have a place in women with a previous history of severe, early-onset disease (eg, CLASP, 1994) 218 and in those with thrombo-embolic disease, but not in the general population. Nor does calcium supplementation; 219 in fact, as the recent title of a paper suggests: 'Prevention of pre-eclampsia is a big disappointment'. 220 That said, a recent placebo-controlled pilot study (n = 283) of dietary supplementation with vitamins C and E reported a decreased incidence of PE and an improvement in plasma markers of endothelial activation and placental dysfunction. 122 Funding is being sought to conduct a large-scale trial, but this is likely to be blurred by women self-medicating following the widespread publicity surrounding publication of the trial. The convincing demonstration that magnesium sulphate is the treatment of choice for the prevention of recurrent eclamptic fits 221 has led to the ongoing MAGPIE trial, investigating its utility in preventing fitting in women with PE. The relative ease of use and cheapness of magnesium sulphate, and the possibility of monitoring for toxic levels through clinical observation rather than expensive laboratory measurement makes this a potentially very valuable prophylactic treatment for the developing world, where PE kills numerous women each year.
Conclusion
The upsurge in research into the pathophysiology of PE over the last 20 years has still further emphasised the protean presentation and multifactorial nature of the disease. In some women, pregnancy seems to be unmasking underlying hypertensive disease which will become manifest in later life. In others, the blood pressure can reach life-threatening levels in a terrifyingly short space of time, only to subside nearly as fast after delivery, and never to recur. In between is all the spectrum familiar to obstetricians. It is possible to speculate that mild, late-onset GH which usually occurs without detriment to fetal well-being, and in some studies in association with increased birthweight is in fact a physiological response to an inadequate utero-placental blood flow. This might 'account for' its high prevalence, and would imply that, although careful monitoring is still needed in case of progression, antihypertensive therapy is not needed. PE might then represent a breakdown of this homeostatic mechanism, in any one of a number of systems.
It is a condition or cluster of conditions with aspects which can interest those with research expertise in a wide variety of fields, and it will be through multidisciplinary research that the pathophysiology is unravelled. The techniques of molecular biology must be put into the context of integrated physiology and clues from the new genetics be interpreted in the light of environmental factors. And finally, we should never lose sight of the fact that in the developing world the hypertensive diseases of pregnancy remain major killers of young women. Their needs are all too often overlooked, but we should try to put results from sophisticated research into their context, as well as our own.
